{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T15:00:28Z","timestamp":1770822028957,"version":"3.50.1"},"reference-count":25,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T00:00:00Z","timestamp":1358208000000},"content-version":"vor","delay-in-days":10607,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[1984,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Of a total of 235 Stage I and II Hodgkin's disease patients treated between 1970 and 1979, 103 (43\u00b78 per cent) had mediastinal involvement in 45 of whom the disease was bulky and in 58 non\u2010bulky. This report concentrates on bulky disease patients of whom 45 per cent did not relapse after therapy and 71 per cent are alive. Patients with mediastinal disease were treated with radiotherapy (63), sequential chemo\u2010radiotherapy (37) or chemotherapy alone (3). In the radiotherapy group the relapse rate for bulky disease was significantly higher (65 per cent) than for non\u2010bulky disease (44 per cent) (<jats:italic>P<\/jats:italic> &lt; 0\u00b705) although there was no significant difference in survival. Neither relapse rate nor survival differed significantly in bulky disease patients treated with radiotherapy compared with combined chemo\u2010radiotherapy although there was a 20 per cent difference in relapse\u2010free survival rate in favour of the combined treatment group at five years. Treatments were not allocated randomly and the chemo\u2010radiotherapy group contained a disproportionate number of patients with adverse features (&gt; 3 node areas involved, limited lung extension) compared with the irradiated group: 11\/25 and 2\/17 respectively. The number of lymph node areas involved appeared to influence the relapse rate in the radiotherapy group. There was no correlation between mediastinal mass size and number of node areas involved suggesting that these two features may be independent prognostic factors.<\/jats:p>","DOI":"10.1002\/hon.2900020106","type":"journal-article","created":{"date-parts":[[2013,1,15]],"date-time":"2013-01-15T10:37:50Z","timestamp":1358246270000},"page":"45-59","source":"Crossref","is-referenced-by-count":27,"title":["Bulky mediastinal Hodgkin's disease management and prognosis"],"prefix":"10.1002","volume":"2","author":[{"given":"K. H.","family":"Liew","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Easton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Horwich","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. J.","family":"Peckham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,1,15]]},"reference":[{"key":"e_1_2_1_2_1","first-page":"1860","article-title":"Report of the Committee on Hodgkin's disease staging classification","volume":"31","author":"Carbone P. P.","year":"1971","journal-title":"Cancer Res."},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197606)37:6<2813::AID-CNCR2820370637>3.0.CO;2-S"},{"key":"e_1_2_1_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2900020105"},{"key":"e_1_2_1_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(80)90315-6"},{"key":"e_1_2_1_6_1","first-page":"789","article-title":"Stage I and II Hodgkin's disease: Involved\u2010field radiotherapy versus extended field radiotherapy versus involved\u2010field radiotherapy followed by six cycles of MOPP","volume":"66","author":"Hagemeister F. B.","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_7_1","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/blood.V59.3.455.455","article-title":"The management of stage I\u2013II Hodgkin's disease with irradiation alone or combined modality therapy: The Stanford experience","volume":"59","author":"Hoppe R. T.","year":"1982","journal-title":"Blood"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1979.27"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19801201)46:11<2403::AID-CNCR2820461116>3.0.CO;2-9"},{"key":"e_1_2_1_10_1","first-page":"819","article-title":"Results of lung irradiation for Hodgkin's disease patients with larger mediastinal masses and\/or hilar disease","volume":"66","author":"Lee C. K. K.","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(77)90274-1"},{"key":"e_1_2_1_12_1","first-page":"809","article-title":"Influence of mediastinal adenopathy on site and frequency of relapse in patients with Hodgkin's disease","volume":"66","author":"Mauch P.","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197809)42:3<1039::AID-CNCR2820420302>3.0.CO;2-R"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(196806)21:6<1100::AID-CNCR2820210610>3.0.CO;2-W"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.3.5713.7"},{"key":"e_1_2_1_16_1","doi-asserted-by":"publisher","DOI":"10.1148\/101.2.441"},{"key":"e_1_2_1_17_1","first-page":"118","volume-title":"Hodgkin's disease","author":"Peckham M. J.","year":"1973"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1975.239"},{"key":"e_1_2_1_19_1","first-page":"691","volume-title":"Treatment of Cancer","author":"Peckham M. J.","year":"1982"},{"key":"e_1_2_1_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(76)90006-7"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/0360-3016(80)90316-8"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197808)42:2 <991::AID-CNCR2820420722>3.0.CO;2-A"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(197903)43:3<1101::AID-CNCR2820430348>3.0.CO;2-3"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(79)90138-5"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2964(80)90254-6"},{"key":"e_1_2_1_26_1","first-page":"711","article-title":"Hodgkin's disease with direct extension into pulmonary parenchyma from a mediastinal mass: A presentation requiring special therapeutic considerations","volume":"66","author":"Wiernik P. H.","year":"1982","journal-title":"Cancer Treat. Rep."}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.2900020106","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.2900020106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,20]],"date-time":"2023-10-20T04:51:47Z","timestamp":1697777507000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.2900020106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1984,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[1984,1]]}},"alternative-id":["10.1002\/hon.2900020106"],"URL":"https:\/\/doi.org\/10.1002\/hon.2900020106","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[1984,1]]}}}